The Center for Oncoendocrinology at Brigham and Women’s Hospital was established to provide expert endocrine care for cancer patients during and after treatment. Endocrinologists at the Center, a program of Dana-Farber/Brigham and Women’s Cancer Center, can provide specialized knowledge of endocrine issues that may affect your cancer patient.
With the help of artificial intelligence, researchers from Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) have developed an early diagnostic tool for ovarian cancer that shows equal sensitivity but far fewer false positives than previous testing strategies. Read More
Specialists in the Thyroid Cancer Center at Dana-Farber/Brigham and Women’s Cancer Center are providing targeted treatments to improve outcomes for patients with advanced and aggressive thyroid cancers in the new Thyroid Cancer 360 Program. Read More
Hemato-oncologists at the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center are leading studies of innovative immunologic approaches for patients with multiple myeloma that are designed to achieve long-term control of the disease. Read More
Dana-Farber/Brigham and Women’s Cancer is one of few centers in the country certified to offer this new approach.
Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women’s Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) on Oct.19. Dana-Farber/Brigham and Women’s Cancer Center was the only facility in the northeast to be part of the clinical trial that led to FDA approval and is one of a few locations certified to offer this new therapy nationwide. Read More
In a groundbreaking study, experts at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) showed that a personalized cancer vaccine, which targets neoantigens, stimulated a potent, safe and highly specific anti-tumor response in six patients with melanoma. Read More